Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Monica Schadlow

Dermatology New York, NY Medical Doctor

NPI 1447255427 CMS profile 292237

820 2Nd Ave, Suite 3A, New York, NY 10017

Open in the dashboard

General payments

$20,551

941 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monica Schadlow of New York, NY is reported in the CMS Open Payments database as having received $20,551 across 941 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,390 146
2024 General $2,261 128
2023 General $3,553 193
2022 General $2,794 152
2021 General $2,855 134
2020 General $2,862 76
2019 General $2,836 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monica Schadlow
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Monica Schadlow were reported at $3,390. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Monica Schadlow Dermatology median Middle half National median
2019 $2,836 $454 $129–$1,240 $163
2020 $2,862 $235 $81–$756 $114
2021 $2,855 $377 $108–$1,108 $132
2022 $2,794 $514 $143–$1,391 $149
2023 $3,553 $607 $159–$1,674 $160
2024 $2,261 $751 $204–$1,903 $164
2025 $3,390 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $3,688 68 payments
  2. AbbVie, Inc. $2,598 156 payments
  3. Janssen Biotech, Inc. $1,830 87 payments
  4. Lilly USA, LLC $1,351 71 payments
  5. Sun Pharmaceutical Industries Inc. $1,241 63 payments
  6. Novartis Pharmaceuticals Corporation $1,211 56 payments
  7. Genzyme Corporation $798 32 payments
  8. Pfizer Inc. $762 40 payments
  9. UCB, Inc. $729 45 payments
  10. Incyte Corporation $702 48 payments
  11. Other $5,641 275 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,745 934 payments
  2. Consulting Fee $1,313 1 payment
  3. Education $494 6 payments
Products named General payments · program years 2019–2025
  1. ORACEA $2,232 15 payments
  2. TREMFYA $1,795 85 payments
  3. EPIDUO FORTE $1,361 22 payments
  4. SKYRIZI $1,334 80 payments
  5. TALTZ $1,329 70 payments
  6. SOOLANTRA $950 20 payments
  7. DUPIXENT $914 31 payments
  8. AKLIEF $787 13 payments
  9. COSENTYX $781 39 payments
  10. OPZELURA $702 48 payments
  11. Other $12,304 657 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

847

Median for Dermatology: 534

Drug cost

$20,897

Median for Dermatology: $67,151

Branded share of claims

6.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pimecrolimus Generic 17 $3,081
Tacrolimus Generic 22 $2,164
Clobetasol Propionate Generic 58 $2,151
Ciclopirox Generic 36 $1,476
Doxycycline Hyclate Generic 49 $1,383
Fluorouracil Generic 20 $1,221
Fluocinonide Generic 45 $1,199
Ammonium Lactate Generic 57 $1,089
Metronidazole Generic 23 $1,082
Clindamycin Phosphate Generic 33 $908

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$187,588

Of which drugs: $4,990

Medicare patients

801

Average age 77

Services billed

3,180

592 women, 209 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 49%
Osteoporosis 30%
Ischemic heart disease 27%
Cancer 25%
Diabetes 14%
Atrial fibrillation 12%
Depression 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 15 16 $4,953
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 50 $37

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$253 — —
COSENTYX
$248 — —
SKYRIZI
$245 — —
Zoryve
$215 — —
Bimzelx
$208 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

941 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record